ReviewInternational journal of hematology2010
Evi-1 as a critical regulator of leukemic cells.
Review in International journal of hematology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- MECOM promotes leukemia progression and inhibits mast cell differentiation through functional competition with GATA2.Leukemia · 2026Article
- CRISPR-Cas9-mediated deletion enhancer of MECOM play a tumor suppressor role in ovarian cancer.Functional & integrative genomics · 2024Article
- Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies.International journal of molecular sciences · 2022Review
- PRDM paralogs antagonistically balance Wnt/β-catenin activity during craniofacial chondrocyte differentiation.Development (Cambridge, England) · 2022Article
- The conserved and divergent roles of Prdm3 and Prdm16 in zebrafish and mouse craniofacial development.Developmental biology · 2020Article
- Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway.Journal of Cancer · 2020Article
- EVI‑1 acts as an oncogene and positively regulates calreticulin in breast cancer.Molecular medicine reports · 2019Article
- Imbalanced expression of polycistronic miRNA in acute myeloid leukemia.International journal of hematology · 2017Article
- Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.Cancer science · 2017Review
- Article
- The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.Nature medicine · 2017Article
- Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.Oncogene · 2016Article
- Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification.BMC research notes · 2016Article
- EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.Cancer science · 2015Article
- The subtype-specific features of EVI1 and PRDM16 in acute myeloid leukemia.Haematologica · 2015Article
- Article
- Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.PloS one · 2014Article
- Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.International journal of hematology · 2013Article
- The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ecotropic viral integration site-1 (EVI-1) has been recognized as one of the dominant oncogenes associated with murine and human myeloid leukemia. Recent clinical studies demonstrated that high EVI-1 expression was an independent negative prognostic indicator of survival in leukemia patients. In addition, gene-targeting studies in mice reveal that Evi-1 is preferentially expressed in hematopoietic stem cells (HSCs) and plays an essential role in proliferation/maintenance of HSCs. Proteins associated with EVI-1, signaling pathways regulated by EVI-1, and downstream mediators of EVI-1 transcriptional regulation have been described and characterized. In this study, we summarize current knowledge regarding biochemical properties and biological functions of EVI-1, which provides a foundation for the development of novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.